Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05996432 · ClinicalTrials.gov registry record · Early Phase 1

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

A Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Brain Metastases, sponsored by Vanderbilt-Ingram Cancer Center.

Recruiting
Registry status
Early Phase 1
Development phase
48
Enrollment target
1
Study location

NCT05996432: Recruiting Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Brain Metastases, sponsored by Vanderbilt-Ingram Cancer Center.

NCT05996432 is a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Brain Metastases that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 48 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05996432, a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Brain Metastases, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.

RECRUITING
Registry status
Early Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.

Primary Outcome

MRI assessed oxygen extraction fraction (OEF, %)

Interventions

  • PROCEDURE Magnetic Resonance Imaging (MRI)
  • PROCEDURE Positron Emission Tomography (PET)
  • DRUG 18F-fluoromisonidazole

Study Locations (1)

Tennessee

  • Vanderbilt University/Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2023-05-17
Est. Completion 2029-05-31
Phase Early Phase 1
Vanderbilt-Ingram Cancer Center

189 total trials

What NCT05996432 shows while recruiting

NCT05996432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (59% lower).

The record links to 2 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.

NCT05996432 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT05996432 about?

NCT05996432 is a clinical study titled "Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy". This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.

What is the current status of trial NCT05996432?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2023-05-17. Estimated completion is 2029-05-31.

What conditions does trial NCT05996432 study?

This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Brain Metastases.

What interventions are being tested in trial NCT05996432?

The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Positron Emission Tomography (PET) (PROCEDURE), 18F-fluoromisonidazole (DRUG).

Who is sponsoring clinical trial NCT05996432?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05996432 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05996432's enrollment target sits among peer trials

48 69th of 124 higher than 56 of 124 other Head and Neck Squamous Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05996432, the US trial registry maintained by the National Library of Medicine. NCT05996432 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.